Tryp Therapeutics Stock Earnings Per Share
| TRYPFDelisted Stock | USD 0.05 0 6.89% |
Tryp Therapeutics fundamentals help investors to digest information that contributes to Tryp Therapeutics' financial success or failures. It also enables traders to predict the movement of Tryp OTC Stock. The fundamental analysis module provides a way to measure Tryp Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tryp Therapeutics otc stock.
Tryp |
Tryp Therapeutics OTC Stock Earnings Per Share Analysis
Tryp Therapeutics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Tryp Therapeutics Earnings Per Share | (0.13) X |
Most of Tryp Therapeutics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tryp Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Tryp Therapeutics has an Earnings Per Share of -0.128 times. This is 101.53% lower than that of the Healthcare sector and 97.33% lower than that of the Biotechnology industry. The earnings per share for all United States stocks is 104.1% higher than that of the company.
Tryp Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tryp Therapeutics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Tryp Therapeutics could also be used in its relative valuation, which is a method of valuing Tryp Therapeutics by comparing valuation metrics of similar companies.Tryp Therapeutics is currently under evaluation in earnings per share category among its peers.
Tryp Fundamentals
| Return On Equity | -9.22 | |||
| Return On Asset | -2.05 | |||
| Current Valuation | 4.17 M | |||
| Shares Outstanding | 96.42 M | |||
| Shares Owned By Insiders | 47.24 % | |||
| Shares Owned By Institutions | 0.04 % | |||
| Price To Book | 2.50 X | |||
| EBITDA | (7.36 M) | |||
| Net Income | (7.49 M) | |||
| Cash And Equivalents | 2.85 M | |||
| Cash Per Share | 0.03 X | |||
| Current Ratio | 6.14 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (5.81 M) | |||
| Earnings Per Share | (0.13) X | |||
| Beta | -1.29 | |||
| Market Capitalization | 6.56 M | |||
| Total Asset | 2.34 M | |||
| Z Score | -9.9 | |||
| Net Asset | 2.34 M |
About Tryp Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tryp Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tryp Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tryp Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Tryp OTC Stock
If you are still planning to invest in Tryp Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tryp Therapeutics' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |